Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
March 10, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in...
Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
January 27, 2023 07:29 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two...
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
January 27, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDAPhase 3...
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022 04:00 ET
|
Sol-Gel Technologies Ltd.
Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel’s cash runway expected to extend through the end of the first quarter of 2024NESS ZIONA,...
Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
October 03, 2022 08:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded...
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022 06:00 ET
|
Sol-Gel Technologies Ltd.
Prescription volumes to date indicate strong uptake, similar to successful dermatology launches Sol-Gel receives $3.5 million milestone payment from commercial partner Galderma Holding SA...
Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference
June 01, 2022 08:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded...
Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference
May 17, 2022 07:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded...
Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 13, 2022 07:00 ET
|
Sol-Gel Technologies Ltd.
FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is patent protected until 2040Partner Galderma to launch two...
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
April 25, 2022 07:00 ET
|
Sol-Gel Technologies Ltd.
EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040 Galderma...